A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.

Phase 2

Pfizer

Sunitinib